Developing personalized biomarkers for melanoma treatment
NYU Melanoma SPORE
This study is working to make melanoma treatments more effective by finding personalized markers that can help doctors predict how well patients will respond to immunotherapy and what side effects they might experience, so that each patient can get the best care possible.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10652334 on NIH RePORTER |
What this research studies
This research focuses on improving the effectiveness of immune checkpoint inhibition therapies for melanoma by developing personalized biomarkers that can predict patient response and potential side effects. By integrating these biomarkers into clinical care, the goal is to optimize treatment selection for patients receiving immunotherapy. The research involves a phased approach, starting from identifying relevant biomarkers to validating them through clinical assays. This comprehensive strategy aims to enhance the overall management of melanoma and potentially other cancers treated with similar therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who are considering or currently undergoing immune checkpoint inhibition therapy.
Not a fit: Patients with melanoma who are not eligible for immune checkpoint inhibition therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for melanoma patients through personalized therapy.
How similar studies have performed: Other research has shown promising results in developing biomarkers for predicting responses to immunotherapy, indicating that this approach has potential for success.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Osman, Iman — New York University School of Medicine
- Study coordinator: Osman, Iman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.